[Adriamycin effects of PHA-stimulated lymphocytes].
The effect of adriamycin on PHA-stimulated lymphocytes is dose-dependent. An adriamycin concentration of 0.2 mug/ml reduces blast transformation and RNA synthesis as well as cell proliferation (DNA-synthesis). The lower concnetration of 0,01 mug/ml, which can be found inpatients for several hours after i.v. application, results only in a transitional inhibition of uridine nucleolar labelling. This inhibition of uridine nucleolar labelling appears more rapidly after adriamycin addition than that of thymidine labelling. Lymphocytes preincubated with adriamycin are effected similarly to lymphocyte cultured in the continuous presence of adriamycin.
D002455:Cell Division / Q000187:drug effects; D004247:DNA / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000494:pharmacology*; D006801:Humans; D007275:Injections, Intravenous; D037102:Lectins / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000187:drug effects* / Q000378:metabolism; D012313:RNA / Q000096:biosynthesis; D013936:Thymidine / Q000378:metabolism; D013997:Time Factors; D014529:Uridine / Q000378:metabolism
D037102:Lectins; D012313:RNA; D004317:Doxorubicin; D004247:DNA; D013936:Thymidine; D014529:Uridine
Wirkungen von Adriamycin auf PHA-stimulierte Lymphozyten